Short answer
ACADIA PHARMACEUTICALS INC (ACAD) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Six-month financial results through June 30, 2026 announced on August 4, 2026.
ACADIA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Six-month financial results through June 30, 2026 announced on August 4, 2026
- Detailed results and management commentary furnished in Exhibit 99.1
- Investor focus: revenue, operating expenses, cash position, and updated outlook in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $308M, up 16%; DAYBUE $125M rose 30%, while NUPLAZID $183M increased 9% GAAP
- 2026 revenue guidance raised to $1.24–$1.30B, with DAYBUE guidance increased to $480–$510M
- Net income $32M, or $0.18 diluted EPS, versus $27M and $0.16 in Q2 2025
- Cash and investments reached $956M versus $820M at December 31, 2025, supporting pipeline investment
- Remlifanserin Phase 2 Alzheimer’s psychosis results expected September–October 2026, a key clinical catalyst with FDA Fast Track designation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACADIA PHARMACEUTICALS INC 8-K filings
Get the next ACAD 8-K as it lands
Follow ACAD for push alerts, or ask the research agent what this filing means.